Advanced therapy medicinal products (ATMPs) are groundbreaking, innovative treatments for many patients once considered untreatable...

Since the first DCAT Annual Dinner, which was held in 1926, New York City has played host to the multifaceted global event, DCAT Week...

Thanks to the foundational work of the Human Genome Project, which was completed over two decades ago in 2003, biopharmaceutical research and development has made great strides forward...

Traditional blockbuster therapies — high-volume, broad-scope drugs — are being rapidly superseded by high-precision, niche therapeutic platforms that target specific genetic pathways...

Traditionally, randomized controlled trials (RCTs) have been thought of as the gold standard when it comes to demonstrating the efficacy of an investigational drug product...

The clinical trial sector is currently experiencing an evolution thanks to various technological and approach innovations that is equivalent to the transition from paper to Electronic Data Capture (EDC) two decades ago...

The margin for error within drug development is becoming ever narrower, as R&D costs continue to rise, competition pressures intensify, and regulatory expectations grow…

Antibody-based therapeutics have revolutionized modern medicine through their remarkable specificity and efficacy in targeting cancer, autoimmune, and infectious diseases. More than 100 monoclonal antibodies (mAbs) have gained global clinical approval, reflecting their immense therapeutic demand...

Now that the latest J.P. Morgan Healthcare Conference has closed its doors and the dust has started to settle on the discussions and sentiments realized from event, the global bio/pharma industry is optimistic for M&A momentum in 2026...

Geopolitical challenges were on the ordre du jour for many industries in 2025, of particular concern were the U.S.-imposed tariffs, which shook global economies…

“We are definitely seeing that formulations and APIs are becoming more complex and this does present unique challenges for primary packaging,” notes Dr. Robert Lindner, Global Product Manager for Bulk and Sterile Cartridges at SCHOTT Pharma...

Currently, the bio/pharma investment landscape is quite different from what it was less than a decade ago, notes Julien Meissonnier, Independent Director on the Board for Prolific Machines and former Chief Scientific Officer for Catalent…

In order to respond to the rising prevalence of chronic diseases worldwide, it has been necessary for the bio/pharmaceutical industry to innovate across the whole development lifecycle — from discovery through to formulation and manufacturing...

Chronic respiratory disorders, such as chronic obstructive pulmonary disease, asthma, allergic rhinitis, and sinusitis, are becoming increasingly prevalent and considered to be “major contributors to the growing global burden of non-communicable diseases.”…

Various global and market-specific trends are transforming the bio/pharmaceutical industry, leading to the need for new strategies and investment across the full value chain...

The latest edition of CPHI Frankfurt wrapped on Thursday Oct. 30, 2025 after welcoming approximately 62,000 visitors from over 166 countries, making it the largest ever CPHI event. Over 2,500 exhibitors attended the 36th iteration, a vast increase from the event’s humble beginnings back in 1990 when there were only 16 exhibitors…

Given the sheer size of the event, which is growing exponentially year-over-year, a huge amount of planning is required and there are a lot of event happenings that should not be missed, specifies Tara Dougal, Event Director — Pharma at Informa Markets…

An increasingly complex therapeutic development pipeline, global market shifts, a drive for greater cost efficiency, and a need to employ more advanced technologies are some of the key factors leading bio/pharma companies of all sizes to adjust their operational strategies...

The global bio/pharmaceutical industry is facing a crossroads: while therapeutic innovation continues at a rapid pace, the return on investment from such innovation is proving to be less pleasing for company shareholders...

To successfully develop and market a drug product, bio/pharmaceutical companies must adhere to strict regulations and guidelines, which have been set out to ensure quality, efficacy, and safety standards are met...